Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Phase 1
27
about 1.7 years
18+
Female only
1 site in NC
What this study is about
This trial is testing the safety and tolerability of a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) in patients with ovarian cancer that has returned after standard therapy. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration. It team wants to determine a safe dose of the iC9-CAR.B7-H3 T cells, without causing too many side effects.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive iC9-CAR.B7-H3 T cells
- 2.Take Cyclophosphamide
- 3.Take Fludarabine
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine
infusion
Primary: Toxicity: Cytokine Release Syndrome (CRS), Toxicity: Immune effector cell-associated neurotoxicity syndrome (ICANS), Toxicity: NCI-CTCAE
Secondary: Overall Survival (OS), Progression Free Survival (PFS), The disease control rate (DCR)
Oncology